Galecto (NASDAQ:GLTO) Issues Earnings Results

Galecto (NASDAQ:GLTO) released its quarterly earnings data on Wednesday. The company reported ($5.22) earnings per share for the quarter, missing the consensus estimate of ($3.12) by ($2.10), Zacks reports.

Galecto Price Performance

Shares of GLTO traded down $0.13 during trading hours on Thursday, hitting $4.11. The stock had a trading volume of 3,869 shares, compared to its average volume of 18,367. Galecto has a 52 week low of $3.76 and a 52 week high of $21.06. The stock has a market capitalization of $5.41 million, a price-to-earnings ratio of -0.21 and a beta of 1.18. The company’s fifty day moving average is $4.70 and its two-hundred day moving average is $6.68.

About Galecto

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.